FDA clears new St. Jude pacemakers
This article was originally published in The Gray Sheet
Executive Summary
St. Jude has launched its Victory platform of pacemakers in the U.S. and Europe, following Feb. 7 approval by FDA. The products received a European CE Mark late last year. The new product line features pre-programmed settings designed to cut down on implant time, as well as patented technology which the company says minimizes the need for ventricular pacing...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.